Inflammatory responses associated with acute coronary syndrome up-regulate IRAK-M and induce endotoxin tolerance in circulating monocytes

Abstract

Acute coronary syndrome (ACS) groups different cardiac diseases whose development is associated with inflammation. Here we have analyzed the levels of inflammatory cytokines and of members of the TLR/IRAK pathway including IRAK-M in monocytes from ACS patients classified as either UA (unstable angina), STEMI (ST-elevation myocardial infarction) or NSTEMI (non-ST-elevation myocardial infarction). Circulating monocytes from all patients, but not from healthy individuals, showed high levels of pro-inflammatory cytokines, TNF-α and IL-6, as well as of IRAK-M and IL-10. TLR4 was also up-regulated, but IRAK-1, IRAK-4 and MyD88 levels were similar in patients and controls. Further, we investigated the consequences of cytokines/IRAK-M expression on the innate immune response to endotoxin. Ex vivo responses to LPS were markedly attenuated in patient monocytes compared to controls. Control monocytes cultured for 6 h in supplemented medium (10% serum from ACS patients) expressed IRAK-M, and LPS stimulation failed to induce TNF-α and IL-6 in these cultures. Pre-incubation of the serum with a blocking anti-TNF-α antibody reduced this endotoxin tolerance effect, suggesting that TNF-α controls this phenomenon, at least partially. We show for the first time that inflammatory responses associated with ACS induce an unresponsiveness state to endotoxin challenge in circulating monocytes, which correlates with expression of IRAK-M, TLR4 and IL-10. The magnitude of this response varies according to the clinical condition (UA, STEMI or NSTEMI), and is regulated by TNF-α.

Keywords

Acute coronary syndrome IRAK-M cytokines endotoxin tolerance inflammation monocytes

References

Mulvihill NT , Foley JB Inflammation in acute coronary syndromes. Heart 2002; 87: 201—204.

Shishehbor MH , Bhatt DL Inflammation and atherosclerosis. Curr Atheroscler Report 2004; 6: 131—139.

Shinn J. , Edelberg JE , Hong MK Vulnerable atherosclerotic plaque: clinical implications. Curr Vasc Pharmacol 2003; 1: 183—204.

Murtagh BM , Anderson HV Inflammation and atherosclerosis in acute coronary syndromes. J Invasive Cardiol 2004; 16: 377—384.

Kohchi K. , Takebayashi S. , Hiroki T. , Nobuyoshi M. Significance of adventitial inflammation of the coronary artery in patients with unstable angina: results at autopsy. Circulation 1985; 71: 709—716.

van der Wal AC , Becker AE , van der Loos CM , Das PK Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36—44.

Simon AD , Yazdani S. , Wang W. , Schwartz A. , Rabbani LE Elevated plasma levels of interleukin-2 and soluble IL-2 receptor in ischemic heart disease. Clin Cardiol 2001; 24: 253—256.

Nijm J. , Wikby A. , Tompa A. , Olsson AG , Jonasson L. Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol 2005; 95: 452—456.

Wang YN , Che SM , Ma AQ Clinical significance of serum cytokines IL-1β, sIL-2R, IL-6, TNF-α, and IFN-γ in acute coronary syndrome. Chin Med Sci J 2004; 19: 120—124.

10.

Biasucci LM , Liuzzo G. , Grillo RL et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability . Circulation 1999; 99: 855—860.

11.

Albert NM Inflammation and infection in acute coronary syndrome. J Cardiovasc Nurs 2000; 15: 13—26.

12.

Shah PK Plaque disruption and thrombosis: potential role of inflammation and infection . Cardiol Rev 2000; 8: 31—39.

13.

Chyu KY , Shah PK The role of inflammation in plaque disruption and thrombosis. Rev Cardiovasc Med 2001; 2: 82—91.

14.

Paoletti R. , Gotto Jr AM, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation 2004; 109: 20—26.

15.

Hendrix MG , Salimans MM , van Boven CP , Bruggeman CA High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990; 136: 23—28.

16.

Muhlestein JB , Hammond EH , Carlquist JF et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555—1561.

17.

Romano S. , Fratini S. , Di Pietro M et al. Chlamydia pneumoniae infection in patients with acute coronary syndrome: a clinical and serological 1-year follow-up. Int J Immunopathol Pharmacol 2004; 17: 209—218.

18.

Shen CX , Chen HZ , Ge JB The role of inflammatory stress in acute coronary syndrome. Chin Med J 2004; 117: 133—139.

19.

Corti R. , Hutter R. , Badimon JJ , Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis . J Thromb Thrombolys 2004; 17: 35—44.

20.

Ridker PM

Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart

Hosp J 2004; 2: 4—9.

21.

Anders HJ , Banas B. , Schlondorff D. Signaling danger: Toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004; 15: 854—867.

22.

Fan H. , Cook JA Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 2004; 10: 71—84.

23.

Janeway Jr CA , Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197—216.

24.

Li L.

Regulation of innate immunity signaling and its connection with human diseases. Curr Drug Targets Inflamm

Allergy 2004; 3: 81—86.

25.

Lopez-Collazo E. , Fuentes-Prior P. , Arnalich F. , del Fresno C. Pathophysiology of interleukin-1 receptor-associated kinase-M: implications in refractory state. Curr Opin Infect Dis 2006; 19: 237—244.

26.

Medvedev AE , Lentschat A. , Wahl LM , Golenbock DT , Vogel SN Dysregulation of LPS-induced Toll-like receptor 4—MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 2002 ; 169: 5209—5216.

27.

Medzhitov R. , Preston-Hurlburt P. , Kopp E. et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling. Mol Cell 1998; 2: 253—258.

28.

Suzuki N. , Suzuki S. , Yeh WC IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol 2002; 23: 503—506.

29.

Takeda K. , Akira S. TLR signaling pathways. Semin Immunol 2004 ; 16: 3—9.

30.

Zhang FX , Kirschning CJ , Mancinelli R. et al. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem 1999; 274: 7611—7614.

31.

Akira S. , Takeda K. , Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity . Nat Immunol 2001; 2: 675—680.

32.

Mansell A. , Brint E. , Gould JA , O'Neill LA , Hertzog PJ Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-kappaB activation by Toll-like receptor (TLR)-2 and TLR4. J Biol Chem 2004; 279: 37227—37230.

33.

Kolek MJ , Carlquist JF , Muhlestein JB et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004; 148: 1034—1040.

34.

Li C. , Ha T. , Kelley J. , Gao X. , Qiu Y. , Kao RL , Browder W. , Williams DL Modulating Toll-like receptor mediated signaling by (1→3)-β-D-glucan rapidly induces cardioprotection. Cardiovasc Res 2004; 61: 538—547.

35.

Kobayashi K. , Hernandez LD , Galan JE , Janeway Jr CA, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110: 191—202.

36.

Janssens S. , Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 2003; 11: 293—302.

37.

Escoll P. , del Fresno C. , Garcia L. et al. Rapid up-regulation of IRAK-M expression following second endotoxin challenge in human monocytes and in monocytes isolated from septic patients . Biochem Biophys Res Commun 2003; 311: 465—472.

38.

Nakayama K. , Okugawa S. , Yanagimoto S. et al. Involvement of IRAK-M peptidoglycan-induced tolerance in macrophages. J Biol Chem 2004 ; 279: 6629—6634.

39.

del Fresno C. , Otero K. , Gomez-Garcia L. et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 2005; 174: 3032—3040.

40.

Li H. , Cuartas E. , Cui W. et al. IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation. J Exp Med 2005; 201: 1169—1177.

41.

del Fresno C. , Gomez-Garcia L. , Caveda L. et al. Nitric oxide activates the expression of IRAK-M via the release of TNF-α in human monocytes. Nitric Oxide 2004; 10: 213—220.

42.

Hashimoto S. , Morohoshi K. , Suzuki T. , Matsushima K. Lipopolysaccharide-inducible gene expression profile in human monocytes. Scand J Infect Dis 2003; 35: 619—627.

43.

Heagy W. , Hansen C. , Nieman K. , West MA Evidence for a CD14- and serum-independent pathway in the induction of endotoxin-tolerance in human monocytes and THP-1 monocytic cells. Shock 2003; 19: 321—327.

44.

Ziegler-Heitbrock HW. Molecular mechanism in tolerance to lipopolysaccharide . J Inflamm 1995; 45: 13—26.

45.

Sfeir T. , Saha DC , Astiz M. , Rackow EC Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit Care Med 2001; 29: 129—133.

46.

Aso N. , Tamura A. , Kadota J. , Nasu M. Association of peripheral mononuclear cells containing Chlamydia pneumoniae DNA with acute coronary syndrome and stable coronary artery disease. Clin Infect Dis 2004; 39: 366—372.

47.

Miya N. , Oguchi S. , Watanabe I. , Kanmatsuse K. Relation of secretory phospholipase A2 and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes. Circ J 2004; 68: 628—633.

48.

de Kruif MD , van Gorp EC , Keller TT , Ossewaarde JM , ten Cate H. Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research. Cardiovasc Res 2005; 65: 317—327.

49.

Romano S. , Penco M. , Fratini S. et al. Chlamydia pneumoniae infection is associated with coronary artery disease but not implicated in inducing plaque instability. Int J Cardiol 2004; 95: 95—99.